Abstract | BACKGROUND: OBJECTIVES: To explore the effect of edaravone administration on the incidence of sICH in patients with acute LVO receiving apixaban for NVAF. METHODS: A Japanese multicenter registry of apixaban on clinical outcome of the patients with LVO or stenosis (ALVO study) included patients who were admitted within 24 h after stroke onset and were received apixaban within 14 days of stroke onset. Patients were divided into two groups according to edaravone administration ( Edaravone and No- Edaravone groups). The incidence of sICH within one year and infarct growth before apixaban administration were compared between these groups. RESULTS: Of the 686 enrolled patients, 622 were included and edaravone was administered to 407 (65.4%). The incidences of sICH in Edaravone and No- Edaravone groups were 1.3% and 5.0%, respectively (p = 0.01). The inverse probability of treatment-weighting (IPTW) hazard ratio (HR) (95% confidence interval [CI]) of Edaravone group for sICH within one year was 0.36 (0.15-0.80) compared to No- Edaravone group. The incidences of infarct growth in Edaravone and No- Edaravone groups were 35.3% and 42.0%, respectively (p = 0.13). IPTW HR (95% CIs) for infarct growth was 0.76 (0.60-0.97). CONCLUSIONS:
Edaravone administration was associated with a lower incidence of sICH in patients with LVO and NVAF who administrated apixaban.
|
Authors | Takuya Saito, Fumihiro Sakakibara, Kazutaka Uchida, Shinichi Yoshimura, Nobuyuki Sakai, Hirotoshi Imamura, Hiroshi Yamagami, Takeshi Morimoto |
Journal | Journal of the neurological sciences
(J Neurol Sci)
Vol. 453
Pg. 120806
(Oct 15 2023)
ISSN: 1878-5883 [Electronic] Netherlands |
PMID | 37717280
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Elsevier B.V. All rights reserved. |